HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC 50 of 1.3 nM. Antihyperglycemic activities In Vitro HSK0935 (Compound 31) demonstrates excellent hSGLT2 inhibition of 1.3 nM and a high hSGLT1/hSGLT2 selectivity of 843-fold. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo HSK0935 treatment (1, 3, and 10 mg/kg) shows robust urinary glucose excretion in Sprague−Dawley (SD) rats and affects more urinary glucose excretion in Rhesus monkeys . HSK0935 is well tolerated up to 300 mg/kg without any mortality or severe untoward effects in a 28-day repeat-dose toxicology study in beagle dogs . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 1.3 nM (SGLT2)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
HSK0935
CAS number：1638851-44-1 molecular formula：C22H25ClO7
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 1638851-44-1 | molecular formula | C22H25ClO7 |
| molecular weight | 436.88 g/mol | Exact mass | ≥96% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
